{"symbol":"TMO","fiscalQuarter":"Q2-2026","reportDate":"2026-07-22","reportTime":"BMO","status":"upcoming","company":{"name":"Thermo Fisher Scientific Inc.","sector":"Health Care","industry":"Life Sciences Tools & Services"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/TMO/earnings/Q2-2026","preBrief":{"companySnapshot":"Thermo Fisher Scientific Inc. is a leading company in the health care sector, specializing in life sciences tools and services. Their products are essential for research and development in various fields, including pharmaceuticals and diagnostics, making them a key player in advancing health care solutions.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a critical measure of profitability, indicating how much money the company makes for each share of stock.","consensus":"Expected to be around $5.44."},{"name":"Revenue Growth","why":"Revenue growth reflects the company's ability to increase sales and expand its market presence, which is crucial for long-term success.","consensus":"Not available."},{"name":"Gross Margin","why":"Gross margin indicates the efficiency of production and pricing strategy, affecting overall profitability.","consensus":"Not available."}],"lastQuarterRecap":{"summary":"In Q1-2026, Thermo Fisher reported an EPS of $5.44, surpassing expectations by 4.68%. However, the stock declined by 9.20% the following day, indicating market concerns despite the positive earnings surprise.","promises":["Management emphasized their commitment to innovation in life sciences tools.","They highlighted ongoing investments in research and development.","Management expressed confidence in maintaining strong customer relationships."]},"wallStreetExpectations":{"summary":"Analysts are cautiously optimistic about Thermo Fisher's upcoming earnings, given their strong track record of beating EPS estimates. However, the lack of revenue guidance and recent stock performance raises some concerns.","bullCase":"If the company continues its trend of beating EPS estimates, it could signal robust demand for its products, leading to a positive market reaction.","bearCase":"On the other hand, if the earnings report reveals any weakness in revenue growth or margins, it could lead to a significant sell-off, especially given the recent stock decline."},"optionsSignal":{"impliedMove":"14.5%","context":"The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+4.68%","reaction":"-9.20%"},{"quarter":"Q4-2025","epsSurprise":"+2.13%","reaction":"-2.61%"},{"quarter":"Q3-2025","epsSurprise":"+5.31%","reaction":"+1.65%"},{"quarter":"Q2-2025","epsSurprise":"+2.74%","reaction":"+9.14%"},{"quarter":"Q1-2025","epsSurprise":"+1.08%","reaction":"-0.71%"}],"pivotalQuestions":[{"question":"What will the EPS be for Q2-2026?","whyItMatters":"Given the company's history of beating EPS estimates, the actual EPS figure will be crucial for market sentiment."},{"question":"What insights can management provide on revenue growth?","whyItMatters":"Investors are keen to understand the company's growth trajectory, especially in light of recent stock performance."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $5.50 or higher would confirm strong operational performance and investor confidence.","bearTrigger":"An EPS below $5.20 could indicate underlying issues and lead to further stock declines.","context":"The market is weighing the potential for continued earnings growth against concerns about revenue stability."},"scenarioPlaybook":{"beatAndRaise":"If Thermo Fisher beats expectations and raises guidance, history suggests the stock could react positively, averaging a +0.93% move.","inLineCautious":"If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess.","miss":"If the company misses EPS expectations, history suggests a potential decline, with an average reaction of -9.20% following previous misses."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating the potential for Thermo Fisher to exceed EPS expectations again, given their strong track record.","supportingPoints":["The company has consistently beaten EPS estimates in the past, indicating strong operational execution.","Despite recent stock performance, there are no signs of significant demand weakness in their key markets."],"riskToConsensus":"If the EPS comes in below $5.20, it could challenge the current bullish sentiment."},"whatToListenFor":["Any updates on new product launches in life sciences tools.","Insights into customer demand trends in key segments.","Management's outlook on R&D investments and their impact on future growth.","Comments on competitive pressures in the life sciences industry.","Any guidance on revenue expectations for the next quarter."],"metaDescription":"Thermo Fisher Scientific (TMO) reports Q2 2026 earnings July 22. Analysts expect $5.44 EPS. Here's what to watch."}}